82 related articles for article (PubMed ID: 3690531)
1. Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
Foss-Abrahamsen A; Lenner P; Hedenus M; Landys K; Noppa H
Cancer Treat Rep; 1987 Dec; 71(12):1209-12. PubMed ID: 3690531
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas.
Bajetta E; Buzzoni R; Valagussa P; Bonadonna G
Am J Clin Oncol; 1988 Apr; 11(2):100-3. PubMed ID: 3282421
[TBL] [Abstract][Full Text] [Related]
5. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
7. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
10. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
[TBL] [Abstract][Full Text] [Related]
12. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
13. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A
Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061
[TBL] [Abstract][Full Text] [Related]
14. Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Aydogdu I; Koc H; Ilhan O; Gurman G; Akan H; Beksac M; Konuk N; Uysal A; Ozerol E
Haematologia (Budap); 1997; 28(4):207-13. PubMed ID: 9408764
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Haak HL; Gerrits WB; Wijermans PW; Kerkhofs H
Neth J Med; 1993 Apr; 42(3-4):122-7. PubMed ID: 8316324
[TBL] [Abstract][Full Text] [Related]
16. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
17. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
18. [Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):626-9. PubMed ID: 3827258
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
